Compare Incyte Corporation (INCY) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Li Auto Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Li Auto Inc trades at $11.54 (market cap $10.71B). The key difference: Incyte Corporation is far larger — about 2.1× Li Auto Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Li Auto Inc for 101 Days on average.
| INCY | LI | |
|---|---|---|
Market Cap | $22.85B | $10.71B |
Volume | 1,927,029 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $23.13 |
52-Week Low | $83.80 | $10.69 |
Typical Hold Time | 33 Days | 101 Days |
Enterprise Value | $18.35B | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows amid delivery moderation concerns. The stock shows bearish technical signals with negative moving averages and neutral oscillators. Fundamentally, revenue declined to $112.31B in 2025 with net income of $1.12B, though recent quarterly earnings missed expectations. Analyst sentiment is mixed with 44% buy ratings but a consensus price target of $15.18, suggesting 39% upside potential from current levels.
The outlook remains challenging with competitive pressures and cash flow concerns, but the company's strong balance sheet ($112.81B cash) provides cushion. New model launches (Li i9, MEGA) and global expansion could drive recovery, though execution risks and China's auto market weakness pose headwinds. The stock appears undervalued on P/S (0.73) and EV/EBITDA (1.72) metrics relative to growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
